Vaccinogen

As a biotech firm in final translational development for a revolutionary colon cancer vaccine, Vaccinogen came to idfive because it needed to be able to communicate the value of its product to the investment community.

Vaccinogen Image

Obtaining FDA approval for any pharmaceutical product can be both time-consuming and expensive, requiring years of clinical trials and extensive ongoing research before the product is approved.

In order to raise the funding needed for a Phase IIIb clinical trial and to expand their business, Vaccinogen needed a web site that would serve as a platform for attracting investments as well as a place where current investors could go in order to learn about Vaccinogen’s progress. In addition, Vaccinogen needed a platform to communicate with the financial services press and the investment analyst community in order to keep them abreast of their progress.

Idfive created a web site that could serve all of Vaccinogen’s audiences. For potential investors, the media, and the analyst community, the public-facing side of the site was designed to provide an overview of Vaccinogen’s immunotherapy product, the progress it was making towards approval in the US, and its expansion into several international markets. And because information needs to be published quickly in order to meet the needs of today’s 24-hour news cycle (as well as the 24-hour world of international investing), the site had to be able to be updated rapidly by non-technical personnel.

In addition to the public face of the site, idfive needed to create a robust, highly-secure, and rapidly-updatable Investor Extranet for communicating with the institutional investors and private equity firms that have invested in the company. The Extranet was created so that investors could log in to their own private areas, receive confidential communications, and read proprietary reports provided by Vaccinogen.

Receiving FDA approval in the US is an extremely long and complicated process. Thankfully, Vaccinogen is only a few years away from obtaining FDA approval and treating US colon cancer patients. Outside the US, Vaccinogen has already received a Conditional Marketing Authorization ("CMA") in Switzerland - full registration is expected later this year. CMAs are anticipated in Europe and China in early 2010.

As Vaccinogen expands globally and simultaneously moves closer to US FDA approval, the site has performed well as an ongoing resource for the press, analysts, and prospective investors. In fact, since the site launched, Vaccinogen has continued to be successful in raising new rounds of funding by attracting new investors. Current investors have been impressed and extremely satisfied with the instant access to information offered on Vaccinogen’s Investor Extranet, and the Extranet has allowed Vaccinogen to maintain close ties with these investors while strengthening their relationships.

  • Vaccinogen - Home
    Vaccinogen - Home
  • Vaccinogen - Internal
    Vaccinogen - Internal
  • Vaccinogen - Internal
    Vaccinogen - Internal
  • Vaccinogen - Internal
    Vaccinogen - Internal
  • Vaccinogen - Internal
    Vaccinogen - Internal
  • Vaccinogen - Internal
    Vaccinogen - Internal